Overall, the combination therapy showed significant reductions in the primary composite outcome (all-cause hospitalization, all-cause mortality, MACE, MAKE, and MALO) by 13%
Despite a few potential ocular risks caused by GLP-1RAs, more clinical studies continue to discover and confirm their beneficial role in the eye, providing hope for creating a new weapon to treat eye diseases
Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies
When Is the Best Time to Take L-Arginine
However, eligibility criteria may vary, and a healthcare professional can assess whether this medication is appropriate for a specific individual
Cost should be discussed before treatment begins, not after the medication starts working